DE60035485D1 - IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407 - Google Patents

IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407

Info

Publication number
DE60035485D1
DE60035485D1 DE60035485T DE60035485T DE60035485D1 DE 60035485 D1 DE60035485 D1 DE 60035485D1 DE 60035485 T DE60035485 T DE 60035485T DE 60035485 T DE60035485 T DE 60035485T DE 60035485 D1 DE60035485 D1 DE 60035485D1
Authority
DE
Germany
Prior art keywords
mycobacterium
relates
differentially expressed
present
antigenes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60035485T
Other languages
English (en)
Other versions
DE60035485T2 (de
Inventor
Peter Jungblut
Stefan H Kaufmann
Ulrich Schaible
Hans Mollenkopf
Baerbel Raupach
Ursula Zimny-Arndt
Stephanie Lamer
Jens Mattow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of DE60035485D1 publication Critical patent/DE60035485D1/de
Application granted granted Critical
Publication of DE60035485T2 publication Critical patent/DE60035485T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60035485T 1999-01-29 2000-01-28 IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407 Expired - Lifetime DE60035485T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99101590 1999-01-29
EP99101590 1999-01-29
PCT/EP2000/000690 WO2000044392A2 (en) 1999-01-29 2000-01-28 Identification of specific differentially expressed mycobacterial antigens

Publications (2)

Publication Number Publication Date
DE60035485D1 true DE60035485D1 (de) 2007-08-23
DE60035485T2 DE60035485T2 (de) 2008-03-20

Family

ID=8237440

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60035485T Expired - Lifetime DE60035485T2 (de) 1999-01-29 2000-01-28 IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407

Country Status (10)

Country Link
US (1) US7772386B1 (de)
EP (1) EP1146889B1 (de)
JP (1) JP2002534994A (de)
AT (1) ATE366583T1 (de)
AU (1) AU2667600A (de)
CA (1) CA2361246C (de)
DE (1) DE60035485T2 (de)
DK (1) DK1146889T3 (de)
ES (1) ES2288842T3 (de)
WO (1) WO2000044392A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2135947A1 (de) * 2008-06-17 2009-12-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Antagonisten bakterieller Sequenzen
ITRM20100411A1 (it) * 2010-07-23 2012-01-24 Massimo Amicosante Uso di sequenze amminoacidiche da mycobacterium tuberculosis o dei loro corrispondenti acidi nucleici per la diagnosi e la prevenzione di infezione tubercolare, relativo kit diagnostico e vaccino.
CA2941236A1 (en) * 2014-03-07 2015-09-11 Institute For Systems Biology Point of care assays to detect the status of tuberculosis infection
US11679150B2 (en) * 2020-03-03 2023-06-20 The United States Of America, As Represented By The Secretary Of Agriculture Mycoplasma bovis vaccine product
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
KR102405798B1 (ko) * 2020-06-22 2022-06-08 주식회사 미코라파 Rv2882c-Rv2005c 융합 단백질을 포함하는 결핵 면역 치료용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2624759B2 (ja) * 1988-03-30 1997-06-25 味の素株式会社 Bcg菌由来のmpb64蛋白及びその製造法
FR2752425B1 (fr) * 1996-08-19 1998-11-13 Pasteur Institut Fragments d'acides nucleiques specifiques de mycobacteries membres du complexe m. tuberculosis et leurs applications pour la detection et le diagnostic differentiel des membres du complexe m. tuberculosis

Also Published As

Publication number Publication date
EP1146889B1 (de) 2007-07-11
ES2288842T3 (es) 2008-02-01
CA2361246C (en) 2013-04-16
WO2000044392A2 (en) 2000-08-03
AU2667600A (en) 2000-08-18
DE60035485T2 (de) 2008-03-20
CA2361246A1 (en) 2000-08-03
EP1146889A2 (de) 2001-10-24
DK1146889T3 (da) 2007-10-22
ATE366583T1 (de) 2007-08-15
JP2002534994A (ja) 2002-10-22
WO2000044392A3 (en) 2000-12-07
US7772386B1 (en) 2010-08-10

Similar Documents

Publication Publication Date Title
Hanff et al. Humoral immune response in human syphilis to polypeptides of Treponema pallidum.
JP4283872B2 (ja) 微生物蛋白質と、この蛋白質を産生する微生物と、該蛋白質のワクチンおよび結核検出での利用
BRPI0208301A8 (pt) vacinas de ácido nucléico para prevenção de infecção por flavivírus
HUP0105379A2 (hu) Lawsonia intracellularis elleni oltóanyag
DK0950068T3 (da) Kollagen-bindende proteinsammensatninger og fremgangsmade til anvendelse
ATE252640T1 (de) Verbindungen zur immunotherapie und diagnose von tuberkulose
FI895050A0 (fi) Diagnostiska preparat och vaccin foer mykobakterier i folkhaelso-, medicinsk och veterinaermedicinsk praxis.
ATE526994T1 (de) Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
WO2002072036A3 (en) Compositions and methods comprising west nile virus polypeptides
Huang et al. Immunization with cell‐free‐generated vaccine protects from Porphyromonas gingivalis‐induced alveolar bone loss
Hilleman Immunologic, chemotherapeutic and interferon approaches to control of viral disease
Cho et al. Extracellular vesicle-associated antigens as a new vaccine platform against scrub typhus
US7862828B2 (en) Allergy vaccines containing hybrid polypeptides
KR100366482B1 (ko) 백신으로서 정제된 분류가능하지 않은 헤모필루스 인프루엔자 p5단백질, 및 그의 정제방법
DE60035485D1 (de) IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407
Tafuku et al. Japanese encephalitis virus structural and nonstructural proteins expressed in Escherichia coli induce protective immunity in mice
WO2004020609A3 (en) Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
Chelliah et al. Potential DNA vaccine for haemorrhagic septiceamia disease
EP2391640B1 (de) Clostridium-chauvoei-polypeptid, dna, die das polypeptid kodiert, und vakzin, das das polypeptid umfasst
Nassrullah et al. Cloning, Sequencing and Expression of the Brucella Melitensis Novel Lomr Protein.
WO2003102025A1 (fr) Proteine induisant la mort cellulaire d'helicobacter pylori
BR0110791A (pt) Composição, métodos para induzir uma resposta imune em um indivìduo contra um imunogene, para modular o sistema imune de um indivìduo e para imunizar um indivìduo contra um patógeno, vacina recombinante, e patógeno atenuado vivo
BR102019004148A2 (pt) Polipeptídeo ligbnid de leptospira spp. para uso como imunobiológico
WO2022208158A1 (es) Vacunas efectivas para la prevención del botulismo
Ragavendhar et al. Sequence analysis, 3-dimensional protein modelling and epitope prediction of Oma87 gene originating from Pasteurella multocida isolate of sheep

Legal Events

Date Code Title Description
8364 No opposition during term of opposition